• 한국측량학회지
• /
• 제39권3호
• /
• pp.123-132
• /
• 2021

근거리 사진측량에서 스테레오 카메라를 이용하여 3차원 위치를 결정하기 위해 카메라의 내부표정요소뿐만 아니라 카메라 간의 상호표정요소를 결정하는 카메라 캘리브레이션이 선행되어야 한다. 카메라 캘리브레이션을 수행하고 나서 시간이 흐르면 비측량용 카메라의 경우 내부적인 불안정성이나 외부적인 요인에 의해 내부표정요소와 상호표정요소가 변할 수 있다. 본 연구에서는 스테레오 카메라 안정성을 평가하기 위해 두 대의 단일 카메라와 스테레오 카메라의 안정성을 분석뿐만 아니라 검사점을 이용하여 3차원 위치 정확도를 평가하였다. 4개월간 3회의 카메라 캘리브레이션을 수행한 실험을 통해 단일 카메라의 안정성을 평가한 결과 평균제곱근오차는 ±0.001mm로 나타났으며, 스테레오 카메라의 평균제곱근오차는 ±0.012mm ~ ±0.025mm로 나타났다. 또한, 검사점을 이용한 거리정확도를 평가한 결과 ±1mm로 나타나 다시기에 걸쳐 추정한 스테레오 카메라의 내부표정요소와 상호표정요소는 안정적인 것으로 판단되었다.

• Biomolecules & Therapeutics
• /
• 제30권5호
• /
• pp.418-426
• /
• 2022

Chimeric antigen receptor T (CAR-T) cell therapy is one of the promising anticancer treatments. It shows a high overall response rate with complete response to blood cancer. However, there is a limitation to solid tumor treatment. Additionally, this currently approved therapy exhibits side effects such as cytokine release syndrome and neurotoxicity. Alternatively, bispecific antibody is an innovative therapeutic tool that simultaneously engages specific immune cells to disease-related target cells. Since programmed death ligand 1 (PD-L1) is an immune checkpoint molecule highly expressed in some cancer cells, in the current study, we generated αCD3xαPD-L1 bispecific antibody (BiTE) which can engage T cells to PD-L1⁺ cancer cells. We observed that the BiTE-bound OT-1 T cells effectively killed cancer cells in vitro and in vivo. They substantially increased the recruitment of effector memory CD8⁺ T cells having CD8⁺CD44⁺CD62L^low phenotype in tumor. Interestingly, we also observed that BiTE-bound polyclonal T cells showed highly efficacious tumor killing activity in vivo in comparison with the direct intravenous treatment of bispecific antibody, suggesting that PD-L1-directed migration and engagement of activated T cells might increase cancer cell killing. Additionally, BiTE-bound CAR-T cells which targets human Her-2/neu exhibited enhanced killing effect on Her-2-expressing cancer cells in vivo, suggesting that this could be a novel therapeutic regimen. Collectively, our results suggested that engaging activated T cells with cancer cells using αCD3xαPD-L1 BiTE could be an innovative next generation anticancer therapy which exerts simultaneous inhibitory functions on PD-L1 as well as increasing the infiltration of activated T cells having effector memory phenotype in tumor site.

• Molecules and Cells
• /
• 제46권10호
• /
• pp.579-588
• /
• 2023

Sarcomas are rare and heterogeneous mesenchymal neoplasms originating from the bone or soft tissues, which pose significant treatment challenges. The current standard treatment for sarcomas consists of surgical resection, often combined with chemo- and radiotherapy; however, local recurrence and metastasis remain significant concerns. Although immunotherapy has demonstrated promise in improving long-term survival rates for certain cancers, sarcomas are generally considered to be relatively less immunogenic than other tumors, presenting substantial challenges for effective immunotherapy. In this review, we examine the possible opportunities for sarcoma immunotherapy, noting cancer testis antigens expressed in sarcomas. We then cover the current status of immunotherapies in sarcomas, including progress in cancer vaccines, immune checkpoint inhibitors, and adoptive cellular therapy and their potential in combating these tumors. Furthermore, we discuss the limitations of immunotherapies in sarcomas, including a low tumor mutation burden and immunosuppressive tumor microenvironment, and explore potential strategies to tackle the immunosuppressive barriers in therapeutic interventions, shedding light on the development of effective and personalized treatments for sarcomas. Overall, this review provides a comprehensive overview of the current status and potential of immunotherapies in sarcoma treatment, highlighting the challenges and opportunities for developing effective therapies to improve the outcomes of patients with these rare malignancies.

• Korean Journal of Radiology
• /
• 제23권11호
• /
• pp.1089-1101
• /
• 2022

Immunotherapy has revolutionized and opened a new paradigm for cancer treatment. In the era of immunotherapy and molecular targeted therapy, precision medicine has gained emphasis, and an early response assessment is a key element of this approach. Treatment response assessment for immunotherapy is challenging for radiologists because of the rapid development of immunotherapeutic agents, from immune checkpoint inhibitors to chimeric antigen receptor-T cells, with which many radiologists may not be familiar, and the atypical responses to therapy, such as pseudoprogression and hyperprogression. Therefore, new response assessment methods such as immune response assessment, functional/molecular imaging biomarkers, and artificial intelligence (including radiomics and machine learning approaches) have been developed and investigated. Radiologists should be aware of recent trends in immunotherapy development and new response assessment methods.

• IMMUNE NETWORK
• /
• 제22권1호
• /
• pp.3.1-3.21
• /
• 2022

Cancer is one of the leading causes of death worldwide and the number of cancer patients is expected to continuously increase in the future. Traditional cancer therapies focus on inhibiting cancer growth while largely ignoring the contribution of the immune system in eliminating cancer cells. Recently, better understanding of immunological mechanisms pertaining to cancer progress has led to development of several immunotherapies, which revolutionized cancer treatment. Nonetheless, only a small proportion of cancer patients respond to immunotherapy and maintain a durable response. Among multiple factors contributing to the variability of immunotherapy response rates, commensal microbiota inhabiting patients have been identified as one of the most critical factors determining the success of immunotherapy. The functional diversity of microbiota differentially affects the host immune system and controls the efficacy of immunotherapy in individual cancer patients. Moreover, clinical studies have demonstrated that changing the gut microbiota composition by fecal microbiota transplantation in patients who failed a previous immunotherapy converts them to responders of the same therapy. Consequently, both academic and industrial researchers are putting extensive efforts to identify and develop specific bacteria or bacteria mixtures for cancer immunotherapy. In this review, we will summarize the immunological roles of commensal microbiota in cancer treatment and give specific examples of bacteria that show anticancer effect when administered as a monotherapy or as an adjuvant agent for immunotherapy. We will also list ongoing clinical trials testing the anticancer effect of commensal bacteria.

• IMMUNE NETWORK
• /
• 제20권1호
• /
• pp.10.1-10.14
• /
• 2020

Immune checkpoint inhibitors (ICIs) have shown remarkable benefit in the treatment of patients with non-small-cell lung cancer (NSCLC) and have emerged as an effective treatment option even in the first-line setting. ICIs can block inhibitory pathways that restrain the immune response against cancer, restoring and sustaining antitumor immunity. Currently, there are 4 PD-1/PD-L1 blocking agents available in clinics, and immunotherapy-based regimen alone or in combination with chemotherapy is now preferred option. Combination trials assessing combination of ICIs with chemotherapy, targeted therapy and other immunotherapy are ongoing. Controversies remain regarding the use of ICIs in targetable oncogene-addicted subpopulations, but their initial treatment recommendations remained unchanged, with specific tyrosine kinase inhibitors as the choice. For the majority of patients without targetable driver oncogenes, deciding between therapeutic options can be difficult due to lack of direct cross-comparison studies. There are continuous efforts to find predictive biomarkers to find those who respond better to ICIs. PD-L1 protein expressions by immunohistochemistry and tumor mutational burden have emerged as most well-validated biomarkers in multiple clinical trials. However, there still is a need to improve patient selection, and to establish the most effective concurrent or sequential combination therapies in different NSCLC clinical settings. In this review, we will introduce currently used ICIs in NSCLC and analyze most recent trials, and finally discuss how, when and for whom ICIs can be used to provide promising avenues for lung cancer treatment.

• BMB Reports
• /
• 제51권11호
• /
• pp.572-577
• /
• 2018

Recent studies showed that the PD-1/PD-L1 checkpoint blockade is a dramatic therapy for melanoma by enhancing antitumor immune activity. Currently, major strategies for the PD-1/PD-L1 blockade have mainly focused on the use of antibodies and compounds. Seeking an alternative approach, others employ endogenous proteins as blocking agents. The extracellular domain of PD-1 (ePD1) includes the binding site with PD-L1. Accordingly, we constructed a PD-1-based recombinantly tailored fusion protein (dFv-ePD1) that consists of bivalent variable fragments (dFv) of an MMP-2/9-targeted antibody and ePD1. The melanoma-binding intensity and antitumor activity were also investigated. We found the intense and selective binding capability of the protein dFv-ePD1 to human melanoma specimens was confirmed by a tissue microarray. In addition, dFv-ePD1 significantly suppressed the migration and invasion of mouse melanoma B16-F1 cells, and displayed cytotoxicity to cancer cells in vitro. Notably, dFv-ePD1 significantly inhibited the growth of mouse melanoma B16-F1 tumor cells in mice and in vivo fluorescence imaging showed that dFv-ePD was gradually accumulated into the B16-F1 tumor. Also the B16-F1 tumor fluorescence intensity at the tumor site was stronger than that of dFv. This study indicates that the recombinant protein dFv-ePD1 has an intensive melanoma-binding capability and exerts potent therapeutic efficacy against melanoma. The novel format of the PD-L1-blocked agent may play an active role in antitumor immunotherapy.

• 동의생리병리학회지
• /
• 제17권6호
• /
• pp.1383-1392
• /
• 2003

Apoptosis is a morphologically and biochemically district form of cell death that occurs in many different cell types in a wide variety of organisms. Albizzia julibrissin belonging the family Leguminosae has been used for the treatment of contusion, sore throat, amnesia, and insomnia in oriental traditional medicine. This study investigates whether the water extract of A. julibrissin induce apoptotic cell death in Jurkat T-acute lymphoblastic leukemia (ALL) cells. Jurkat cells were increased inhibitions of cell viability in a concentration-dependent manner by A. julibrissin. This herbal medicine also caused apoptosis as measured by cell morphology and DNA fragmentation. The capability of A. julibrissin to induce apoptosis was associated with proteolytic cleavage of specific target proteins such as poly (ADP-ribose)polymerase (PARP) and beta-catenin proteins suggesting the possible involvement of caspases. Our result showed that Bcl-2 and Bax protein levels were not changed in all A. julibrissin-treated groups compared to control group. These results suggest that A. julibrissin-mediated apoptosis is independent with Bcl-2 related signaling pathway in this cells. The purpose of the present study is also to investigate the Effect of A. julibrissin on cell cycle progression. Our results showed that G1 checkpoint related gene products (cyclin D1, cyclin dependent kinase 4, retinoblastoma, E2F1) were decreased in their protein levels in a dose-dependent manners after treatment of the extract. These results indicate that the increase of apoptotic cell death by A. julibrissin may be due to the inhibition of cell cycle progression in wild type p53-lacking Jurkat cells.

• 한국정보과학회논문지:시스템및이론
• /
• 제29권6호
• /
• pp.331-339
• /
• 2002

이 논문은 동기적 검사점 기법에서 결한 포용을 목적으로 불안전 저장 장치(volatile storage)에 저장되는 메시지 로그와 안전 저장 장치에 저장되는 검사점의 쓰레기 처리 기법을 제안한다. 기존의 동기적 검사점 기법을 기반으로 한 결함 포용 정보 쓰레기 처리 기법은 가장 최근의 검사점을 제외한 모든 결함 정보를 쓰레기 처리하였다. 하지만 TCP/IP와 같은 신뢰적 통신 기법을 기반으로 한 동기적 검사점 기법이 가장 최근의 검사점만을 복귀 회복 기법에서 사용한다면, 손실 메시지(lost message)로 인한 불필요한 복귀(sympathetic rollback)가 발생된다. 이 논문은 동기적 검사점 기법에서 손실 메시지로 인한 불필요한 복귀 문제를 해결하기 위해 각 프로세스가 동기화된 가장 최근의 검사정의에 검사점이나 메시지 로그를 유지해야 한다는 것을 보였다. 또한 손실 메시지로 인한 불필요한 복귀 문제의 해결을 위해 관리되어야 하는 검사점이나 메시지 로그가 쓰레기 처리되어지기 위해 필요한 조건을 새롭게 정의하며, 이 정의를 기반으로 한 검사정과 메시지 로그의 쓰레기 처리 알고리즘을 제안한다. 제시된 조건을 기반으로 한 검사점과 메시지 로그의 쓰레기 처리는 송수신 메시지에 부가된 손실 메시지 관련 프로세스 정보를 이용하므로 쓰레기 처리를 위한 부가적인 메시지를 발생시키지 않는다. 제안된 기법은 손실 메시지 관련 정보가 부가된 메시지가 송수신되기 전까지 쓰레기 처리가 지연되는 '지연 쓰레기 처리 현상(lazy garbage collection)'을 발생시킨다. 하지만 '지연 쓰레기 처리 현상'은 분산 시스템의 일관성을 위배하지 않는다.

• 한국정보과학회논문지:시스템및이론
• /
• 제31권3_4호
• /
• pp.204-212
• /
• 2004

분산 시스템에서는 단일 시스템보다 높은 결함 발생 확률을 가지기에 기존의 맡은 연구에서는 분산 시스템에서 결함 발생에 대한 맡은 결함 포용 기법들이 연구되어 왔다. 하지만 저장된 결함 포용 정보의 증가에 따른 저장 공간의 부족으로 인해 전체 시스템 성능의 저하를 가져오게 하였다. 시스템 성능의 저하를 막기 위하여 불필요한 결함 포용 정보의 삭제가 필요하게 되었고 이 논문에서는 결함 포용 정보의 쓰레기 처리를 위한 방법을 제안한다. 이에 본 논문에서는 결함 포용 정보의 쓰레기 처리를 담당하는 쓰레기 처리 에이전트, 결함 포용 정보를 유지 관리하는 정보 에이전트, 그리고 전체 에이전트간의 통신 기능을 담당하는 조정 에이전트를 정의 및 설계하고, 쓰레기 처리 에이전트를 이용한 쓰레기 처리 알고리즘을 제안한다. 복귀회복 기법은 독립 검사점(independent checkpoint)기법과 송신자 기반 비관적 매시지 로깅(sender based pessimistic message logging)기법을 사용한다. 제안된 쓰레기 처리 기법에서의 쓰레기 처리, 정보, 조정 에이전트는 프로세스와 동시에 생성되며 정보 에이전트에 프로세스에서 발생하는 검사점과 비결정적인 사건들에 대한 로깅 정보들을 영역 지식으로 구축한다. 그리고 쓰레기 처리 에이전트는 쓰레기 처리 시점을 선정하고 정보 에이전트와 조정에이전트의 협력을 통하여 영역 지식에 구축된 불필요한 결함 포용 정보의 쓰레기 처리를 한다. 제안한 에이전트를 이용한 쓰레기 처리기법의 타당성 증명을 위하여 결함을 발생시켜 복귀 회복 후 쓰레기 처리를 하는 시스템과 하지 않는 시스템의 영역지식을 비교하여 같은 결과를 같는지의 여부를 검사한다